Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) just unveiled an update.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a plan to repurchase A shares valued between RMB1 billion and RMB2 billion using its own funds, with the aim of implementing an employee stock ownership scheme. The repurchase will be conducted through centralized price bidding in the secondary market, with a maximum price of RMB90.85 per share, and is set to occur within twelve months following board approval. This move is part of the company’s strategic efforts to enhance shareholder value and align employee interests with company performance.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, primarily involved in the development, manufacturing, and sale of pharmaceutical products. The company focuses on innovative drug research and development, with a strong presence in the Chinese market.
Average Trading Volume: 5,972,041
Current Market Cap: HK$457.1B
Learn more about 1276 stock on TipRanks’ Stock Analysis page.